<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04333173</url>
  </required_header>
  <id_info>
    <org_study_id>101010</org_study_id>
    <nct_id>NCT04333173</nct_id>
  </id_info>
  <brief_title>Endovascular Therapy for Erectile Dysfunction</brief_title>
  <acronym>RE-ACTION</acronym>
  <official_title>ENDOVASCULAR THERAPY REGISTRY FOR ERECTILE DYSFUNCTION</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinica San Gaudenzio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinica San Gaudenzio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Brief Summary: Background and pathophysiology Erectile dysfunction is a serious disease with&#xD;
      a significant impact on the quality of life. Male erection is a complex mechanism that&#xD;
      involves neuro-vascular tissue responses with several phases including arterial dilatation,&#xD;
      smooth muscle cells relaxation and ultimately veno-occlusive activation. Vasculogenic&#xD;
      erectile dysfunction can be divided in arteriogenic (when there is insufficiency of arterial&#xD;
      component of erection due to atherosclerotic plaque encroachment of the penile arteries) or&#xD;
      venogenic (where there is insufficiency of the venous component of erection for venous&#xD;
      endoleak) Standard treatment Erectile dysfunction is commonly treated by oral&#xD;
      phosphodiesterase-5-inhbitor (PDE5i) administration. However, up to 50% of men have a&#xD;
      suboptimal response to PDE5-i therapy with the need of additional therapies. New treatment&#xD;
      Only recently several studies have been published on percutaneous treatment of ED using POBA,&#xD;
      Drug eluting balloons (both paclitaxel and sirolimus, PEB and SES) and drug eluting stents&#xD;
      (DES).&#xD;
&#xD;
      Aim of the study The study was aimed at evaluating both arteriogenic and venogenic&#xD;
      endovascular treatments in patients affected by erectile dysfunction in an Italian patient&#xD;
      cohort.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Detailed Description: The objective of this study is to evaluate of the safety and&#xD;
      feasibility of endovascular therapies in segmental atherosclerotic lesions of the internal&#xD;
      pudendal arteries among men with erectile dysfunction (ED) and no-response to&#xD;
      phosphodiesterase-5 inhibitors for at least 6 months either at increasing dosage or with&#xD;
      different drugs routinely utilized in this setting) before enrollment. All patients will be&#xD;
      screened by IIEF-5 questionnaire (IEF-5 Score &lt; 15 points); Penile Dynamic Doppler ultrasound&#xD;
      with intracavernous injection of Caverject (cut-off for Inflow insufficiency: PSV &lt;25 cm s-1,&#xD;
      EDV &lt;5 cm s-1, RI &gt; 0.8; cut-off for Venous leakage: PSV &gt; 25 cm s-1, EDV &gt; 5 cm s-1, RI &lt;&#xD;
      0.8; cut-off for mixed pathology: PSV &lt; 25 cm s-1, EDV &gt; 5 cm s-1, RI &lt; 0.8); and/or positive&#xD;
      angio-CT scan for stenosis of the penile arteries of venous insufficiency. All patients will&#xD;
      be treated either by POBA+PES/SES or in case of suboptimal result (angiographic residual&#xD;
      stenosis &gt; 30%) with DES implantation. All patients will be discharged with dual antiplatelet&#xD;
      therapy for 3 months and with Cialis 5 mg daily for 30 days. Patients will be followed at 1&#xD;
      mos with IIEF questionnaire, 3 months with IIE-5 questionnaire, 8 months with IIEF&#xD;
      questionnaire and Dynamic Doppler ultrasound evaluation, and 12 months with IIEF-5&#xD;
      questionnaire and Dynamic Doppler ultrasound evaluation. Primary endpoints will be the delta&#xD;
      of IEF-5 score between basal and 8 months FU (&gt;5 points). Delta PSV (&gt;8 points of cm/sec at&#xD;
      the Dynamic Doppler evaluation) between basal and 8 mos follow-up. 1. Secondary endpoints&#xD;
      will be a) Incidence of MAE (Death, MI, Stroke), 2) Binary restenosis and late loss in&#xD;
      patients who will repeat control angiography if clinically indicated for ED recurrence&#xD;
      (clinically evaluated by either needs to reintroduce/increase PDEF5i dosage on-demand, delta&#xD;
      IEF-5 &lt;5 compared to 1 mos FU after 6 mos FU) or in patients with bilateral disease with&#xD;
      scheduled procedure after 6 mos FU from the index procedure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2017</start_date>
  <completion_date type="Actual">January 1, 2020</completion_date>
  <primary_completion_date type="Actual">January 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>IEF-5 SCORE VARIATION AFTER ENDOVASCULAR</measure>
    <time_frame>6 months</time_frame>
    <description>INTERNATIONAL INDEX OF ERECTILE FUNCTION</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PSV VARIATION AFTER ENDOVASCULAR TREATMENT</measure>
    <time_frame>6 month</time_frame>
    <description>PUDENDAL DOPPLER PEAK SYSTOLIC VELOCITY</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADVERSE EVENTS</measure>
    <time_frame>6-12 months</time_frame>
    <description>Procedural complications; cardiovascular events during follow-up</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">300</enrollment>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>Active endovascular treatment</arm_group_label>
    <description>Patients with erectile dysfunction (ED) and no-response to phosphodiesterase-5 inhibitors for at least 6 months before enrollment</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>endovascular procedure</intervention_name>
    <description>Endovascular therapies for erectile dysfunction</description>
    <arm_group_label>Active endovascular treatment</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with erectile dysfunction (ED) and no-response to phosphodiesterase-5 inhibitors&#xD;
        for at least 6 months before enrollment&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years old&#xD;
&#xD;
          -  Be able to understand and sign a witnessed informed consent for the procedure&#xD;
&#xD;
          -  Eligibility for percutaneous peripheral intervention&#xD;
&#xD;
          -  Baseline IIEF-5 score evaluation &lt; 15&#xD;
&#xD;
          -  PSV &lt; 25 cm/sec&#xD;
&#xD;
          -  Stable hemodynamic conditions&#xD;
&#xD;
          -  Normal ejection fraction&#xD;
&#xD;
          -  Being refractory to oral PDE5-I for at least 6 months before enrollement&#xD;
&#xD;
          -  Treatable angiographic lesions of the pudendal arteries&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Heart failure&#xD;
&#xD;
          -  Hemodynamic instability&#xD;
&#xD;
          -  Basal IIEF-5 and doppler examination&#xD;
&#xD;
          -  Blood count not within normal ranges&#xD;
&#xD;
          -  No history of bleeding or coagulopathy&#xD;
&#xD;
          -  No other serious medical illness&#xD;
&#xD;
          -  Other investigational drug or device study&#xD;
&#xD;
          -  Pudendal artery &lt; 1.5 mm and lesion lenght greater than 80 mm by visual estimation&#xD;
&#xD;
          -  Pudendal restenosis from previous intervention&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Centro Cuore</name>
      <address>
        <city>Novara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Sangiorgi G, Colantonio R, Antonini G, Savino A, Sperandio M. [Percutaneous intervention therapy for vascular erectile dysfunction]. G Ital Cardiol (Rome). 2016 Oct;17(10 Suppl 1):12S-21. doi: 10.1714/2372.25474. Review. Italian.</citation>
    <PMID>27729664</PMID>
  </reference>
  <reference>
    <citation>Doppalapudi SK, Wajswol E, Shukla PA, Kolber MK, Singh MK, Kumar A, Fischman A, Rastinehad AR. Endovascular Therapy for Vasculogenic Erectile Dysfunction: A Systematic Review and Meta-Analysis of Arterial and Venous Therapies. J Vasc Interv Radiol. 2019 Aug;30(8):1251-1258.e2. doi: 10.1016/j.jvir.2019.01.024. Epub 2019 May 17.</citation>
    <PMID>31104902</PMID>
  </reference>
  <reference>
    <citation>Diehm N, Marggi S, Ueki Y, Schumacher D, Keo HH, Regli C, Do DD, Moeltgen T, Grimsehl P, Wyler S, Schoenhofen H, RÃ¤ber L, Schumacher M. Endovascular Therapy for Erectile Dysfunction-Who Benefits Most? Insights From a Single-Center Experience. J Endovasc Ther. 2019 Apr;26(2):181-190. doi: 10.1177/1526602819829903. Epub 2019 Feb 11.</citation>
    <PMID>30741067</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 1, 2020</study_first_submitted>
  <study_first_submitted_qc>April 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2020</study_first_posted>
  <last_update_submitted>April 1, 2020</last_update_submitted>
  <last_update_submitted_qc>April 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Clinica San Gaudenzio</investigator_affiliation>
    <investigator_full_name>Giuseppe Sangiorgi</investigator_full_name>
    <investigator_title>Prof</investigator_title>
  </responsible_party>
  <keyword>ED</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

